MCX TREDNS
GOLD (3 OCT.) TREND: CONSOLIDATE
RES 1: 28100
RES 2: 28300
SUPP 1: 27700
SUPP 2: 27500
STRATEGY: SELL ON HIGH
SILVER (5 DEC.) TREND: CONSOLIDATE
RES 1: 43200
RES 2: 43500
SUPP 1: 42500
SUPP 2: 42200
STRATEGY: SELL ON HIGH
CRUDEOIL (19 SEP.) TREND: CONSOLIDATE
RES 1: 5860
RES 2: 5900
SUPP 1: 5790
SUPP 2: 5750
STRATEGY: BUY ON DIPS
COPPER (28 NOV.) TREND: CONSOLIDATE
RES 1: 430.00
RES 2: 432.00
SUPP 1: 425.50
SUPP 2: 423.50
STRATEGY: SELL ON HIGH
AGRI | NCDEX TRENDS
CASTORSEED (19 SEP.) TREND: CONSOLIDATE RES1: 4145 RES2: 4175 SUPP1: 4000 SUPP2: 3975 STRATEGY: SELL ON HIGH
TMCFGRNZM (19 SEP.)TREND: CONSOLIDATE RES 1:6590 RES 2:6650 SUPP 1:6455 SUPP 2:6410 STRATEGY: BUY ON DIPS
CHARJDDEL (19 SEP.) TREND: CONSOLIDATE RES 1: 2885 RES 2: 2905 SUPP 1: 2825 SUPP 2: 2785 STRATEGY: SELL ON HIGH
SYBEANIDR (20 OCT.) TREND: CONSOLIDATE RES 1:3315 RES 2:3365 SUPP 1:3240 SUPP 2:3205 STRATEGY: SELL ON HIGH
VISIT US ON stock advisory company in indore or NCDEX tips free trial
GOLD (3 OCT.) TREND: CONSOLIDATE
RES 1: 28100
RES 2: 28300
SUPP 1: 27700
SUPP 2: 27500
STRATEGY: SELL ON HIGH
SILVER (5 DEC.) TREND: CONSOLIDATE
RES 1: 43200
RES 2: 43500
SUPP 1: 42500
SUPP 2: 42200
STRATEGY: SELL ON HIGH
CRUDEOIL (19 SEP.) TREND: CONSOLIDATE
RES 1: 5860
RES 2: 5900
SUPP 1: 5790
SUPP 2: 5750
STRATEGY: BUY ON DIPS
COPPER (28 NOV.) TREND: CONSOLIDATE
RES 1: 430.00
RES 2: 432.00
SUPP 1: 425.50
SUPP 2: 423.50
STRATEGY: SELL ON HIGH
AGRI | NCDEX TRENDS
CASTORSEED (19 SEP.) TREND: CONSOLIDATE RES1: 4145 RES2: 4175 SUPP1: 4000 SUPP2: 3975 STRATEGY: SELL ON HIGH
TMCFGRNZM (19 SEP.)TREND: CONSOLIDATE RES 1:6590 RES 2:6650 SUPP 1:6455 SUPP 2:6410 STRATEGY: BUY ON DIPS
CHARJDDEL (19 SEP.) TREND: CONSOLIDATE RES 1: 2885 RES 2: 2905 SUPP 1: 2825 SUPP 2: 2785 STRATEGY: SELL ON HIGH
SYBEANIDR (20 OCT.) TREND: CONSOLIDATE RES 1:3315 RES 2:3365 SUPP 1:3240 SUPP 2:3205 STRATEGY: SELL ON HIGH
VISIT US ON stock advisory company in indore or NCDEX tips free trial
Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product.
ReplyDeleteFree Equity Tips